Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ES104 in unresectable locally advanced or metastatic colorectal cancer after failure of systemic therapy
CTR20213124Phase 2Terminated
- Sponsor
- Elpiscience
- Start
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tovecimig in colorectal cancer (CRC), sponsored by Elpiscience. Started Feb 2022; status: terminated.
02
Drugs
tovecimig
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20213124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213124.